

Hepatobiliary and Pancreas Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

LOCOREGIONAL

FIRST LINE

SECOND LINE

THIRD LINE

UCI 19-49

Cabo + Ipi/Nivo + TACE

Coord: H. Nguyen
Accrual: 19/35

UCI 22-106

STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab
(Slot request required)

Coord: H. Nguyen
Accrual: 7/10

UCI 23-75/ROUTE 90

Eye90 microspheres

Coord: M. Duron
Accrual: 1/15

UCI 22-211

MED1572 (IgG1 mAb) ± Bev ± Lenvatinib
Slot request required

Coord: C. Kang
Accrual: 3/8

UCI 16-94

TATE + Nivolumab (includes gastric/GEJ)

Coord: S. Duong
Accrual: 29/40

UCI 23-104

Livmoniplimab + Budigalimab
Atezolizumab + Bevacizumab
Tremelimumab + Durvalumab

Coord: S. Duong
Accrual: 3/7

UCI 23-215

AZD5851 (GPC3 Autologous CAR-T)

Cell therapy audit pending

UCI 23-86

Atezolizumab ± Bevacizumab
(Child-Pugh B7 and B8)

Coord: M. Duron
Accrual: 0/10

SYSTEMIC + OPERATIVE

EA2197/OPT-IN

Gemcitabine + Cisplatin: Neo
+ Adjuvant or Adjuvant only
Incidental gallbladder

Coord: J. Balague
Accrual: 0/10

ETCTN 10608

Gemcitabine + Cisplatin +
Durva Neo/Adjuvant for **high-**
risk resectable ICC

Coord: J. Balague
Accrual: 1/3

UCI 23-99

Randomize, adjuvant
Rilvegostomig/placebo +
capecitabine or gem/cisplatin
after BTC resection

Coord: H. Nguyen
Accrual: 0/8

FIRST LINE

UCI 22-212

(includes Ampullary)

Durvalumab + any
gemcitabine-based regimen
LIMITED SLOTS

Coord: H. Nguyen
Accrual: 4/8

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

SECOND LINE+

ETCTN-10276

M3814 ± Avelumab +
Hypofraction Radiation

Coord: C. Kang
Accrual: 3/5

UCI 23-200

AZD0901 (CLND18 ADC)
Central prescreening

Coord: S. Duong
Accrual: 3/10

Tentative Q1 2025



PERIOPERATIVE

A021806
Neo/adjuvant vs adjuvant
mFOLFIRINOX

Coord: J. Balangué
Accrual: 0/15

UCI 22-75
ELI-002 7P (oncolytic virus)
(KRAS Local testing)
Within 6 months of resection
or last adjuvant treatment

Coord: M. Duron
Accrual: 5/7

**BORDERLINE/
LOCALLY ADVANCED**

ETCTN-10366
M3814 (Peposertib) + radiation
therapy
Coord: S. Duong
Accrual: 5/8

ETCTN-10464
Olaparib with Durvalumab +
radiation therapy

Coord: S. Duong
Accrual: 0/5

UCI 23-134
Padeliporfin Vascular targeted
photodynamic therapy

Pancreatic head/uncinate w/SMA

Coord: C. Kang
Accrual: 0/8

FIRST LINE LA/METASTATIC

S2001
Olaparib +/- Pembrolizumab (BRCA
1/2, STABLE DISEASE)

Coord: J. Balangué
Accrual: 2/4

UCI 23-200
AZD0901 (CLND18 ADC) with
NAL-IRI or Gemcitabine
Investigator discretion

Coord: S. Duong
Accrual: 3/10

SECOND LINE

ETCTN 10522
CA4948 + gemcitabine + nab-
paclitaxel

Coord: H. Nguyen
Accrual: 3/4

A022106
Nab-paclitaxel + Gemcitabine ±
Cisplatin
*BRCA1/2 or PALB2
PD on 1L FOLFIRINOX*

Coord: J. Balangué
Accrual: 0/3

RECURRENT METASTATIC

UCI 24-08
SPEDOX -6 (Protein
encapsulated doxorubicin)

Coord: TBD
Pending PRMC

**Review Biomarker Based
Solid Tumors Pages 6 and 7**



ADJUVANT

S2104
Capecitabine + Temozolomide
vs observation

Pancreatic NET Ki67 > 3%

Coord: J. Balangue
Accrual: 0/2

SECOND LINE+

ETCTN 10558
Lu-177 ± Triapine

NET w/positive 68 or 64
DOTATATE on scans

Coord: H. Nguyen
Accrual: 0/3

Mutation based studies allowing Pancreatic, HCC, and Biliary cancers + other solid tumors

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

HER2

UCI 20-67

DF1001 +/- nivo

Coord: M. Nguyen
Accrual: 18/20

TISSUE FACTOR

UCI 21-146

MRG004A (TF ADC)

Coord: M. Duron
Accrual: 5/11

KRAS/NRAS

UCI 21-53

LY3537982 (KRAS G12C Inhibitor)

Coord: J. Choe
Accrual: 7/8

GERMLINE MUTATIONS

ETCTN-10528

Novobiocin (POL0)
Germline mutations

Coord: H. Nguyen
Accrual: 0/5

CLAUDIN 18.2

UCI 22-51

ASP2138 (CLDN18.2)

Pancreatic and
Gastric/GEJ

Coord: J. Balangué and
M. Duron
Accrual: 12/20

EpCAM

UCI 23-85

BA3182 (CAB T-cell:
EpCAM)

All solid tumors (central
EPCAM testing)

Coord: J. Balangué
Accrual: 0/3

UCI 22-87

RMC-6236 (KRAS Inhibitor)

Pancreatic KRAS mutation 1L
Pancreatic KRAS WT 2L

Coord: C. Kang
Accrual: 19/25

EGFR

UCI 22-171

EGFR TriNKET +/-
Nivolumab
(Central testing)

Coord: H. Nguyen
Accrual: 4/15

UCI 24-82

NRAS, KRAS, BRAF mutation
inhibitors

Local testing; contact CRC
for specific tumor types

Coord: C. Kang
Accrual: 0/10



Various solid tumors included, or have progressed on, exhausted all therapies, or not amenable to further treatment

UCI 22-26
CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Coord: M. Duron
Accrual: 8/12

UCI 23-07
P-MUC1C-ALLO1 (CAR-T Cell)

Epithelial-derived cancer

Coord: J. Miranda
Accrual: 0/5

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

BLOOD COLLECTION

UCI 21-124

ctDNA collection during HBP workup

Coord: S.Duong
Accrual: 14/17

UCI 23-10/PRECEDE

(Blood collection for early detection of pancreatic cancer)

Pending budget/contract